Protein, peptide and non-peptide drug PEGylation for therapeutic application

Bibliography

• KOPE EK J, KOPECKOVA P, MINKO T, LU Z: HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. I Pharm. Biopharm. (2000) 50:61–81.
   PubMed Web of Science ®Google Scholar
• HARRIS JM, CHESS RB: Effect of PEGylation on pharmaceuticals. Nat. Rev Drug Discov. (2003) 2:214–221.
   PubMed Web of Science ®Google Scholar
• •A complete overview of protein PEGylation.
   Google Scholar
• VERONESE FM, MORPURGO M: Bioconjugation in pharmaceutical chemistry. Fermat.° (1999) 54:497–516.
   Google Scholar
• BAILON P, BERTHOLD W: Polyethylene glycol-conjugated pharmaceutical proteins. Aerial Sci Technol Today (1998) 1:352–356.
   Google Scholar
• HARRIS JM, ZAPLISKY S: Poly (ethylene glycol) Chemistry and biological application . San Francisco (1997) Am. Chem. Soc. Symposium Series 680:1–15.
   Google Scholar
• VERONESE FM: Peptide and protein PEGylation: a review of problems and solutions. Biomaterials (2001) 22:405–417.
   PubMed Web of Science ®Google Scholar
• •A helpful review on PEGylatiaon chemistry.
   Google Scholar
• RUSSELL-JONES GJ: The potential use of receptor-mediated endocytosis for oral drug delivery. Adv. Drug Deify. Rev (1996) 20:83–97.
   Web of Science ®Google Scholar
• OKAMOTO CT: Endocytosis and transcytosis. Adv. Drug Deity. Rev (1998) 29:215–228.
   PubMed Web of Science ®Google Scholar
• TAKAKURA Y, MAHOTO RI, HASHIDA M: Extravasation of macromolecules. Adv. Drug Deify. Rev (1998) 34:93–108.
   PubMed Web of Science ®Google Scholar
• DAVIS FE ABUCHOWSKI A, VAN ES T et al.: Enzyme polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng. (1978) 4:169–173.
   Google Scholar
• HARRIS JM, MARTIN NE, MODI M: PEGylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. (2001) 40:539–551.
   PubMed Web of Science ®Google Scholar
• DAVIS FE KAZO GM, NUCCI ML, ABUCHOWSKI A: Peptide and protein drug delivery Lee VHL (Ed.) Marcel Dekker, New York, USA (1990):226–231.
   Google Scholar
• NUCCI ML, SCHORR R, ABUCHOWSKI A: The therapeutic value of polyethylene glycol modified protein. Adv. Drug Deify. Rev. (1991) 6:133–151.
   Web of Science ®Google Scholar
• LEVY Y, HERSHFIELD MS, FERNANDEZ -MEJIA C et al.: Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. Pediab: (1988) 113:312–317.
   Google Scholar
• GRAHAM LM: PEGasparaginase: A reviewof clinical studies. Adv. Drug Deify. Rev. (2003) 10:1293–1302.
   Google Scholar
• WANG YS, YOUNGSTER S, GRACE M, BAUSCH J, BORDENS R, WYSS DF: Structural and biological characterisation of pegylated recombinant interferon a-2b and its therapeutic implications. Adv. Drug Deli v. Rev. (2002) 54:547–570.
   PubMed Web of Science ®Google Scholar
• BAILON P, PALLERONI A, SCHAFFER CA et al.: Rational design of a potent, long-lasting form of interferon: a 40 KDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis C. Bioconjugate Chem. (2001) 12:195–202.
   PubMed Web of Science ®Google Scholar
• •Description of the approach to the preparation of a PEG-protein conjugate.
   Google Scholar
• REDDY KR, MODI MW, PEDDER S: Use of PEGinterferon a 2a (40KD) (Pegasys) for the treatment of hepatitis C . Adv. Drug Deify. Rev. (2002) 54:571–586.
   PubMed Web of Science ®Google Scholar
• TRAINER PJ, DRAKE WM, KATZNELSON L et al.: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. Med. (2000) 342(16):1171–1177.
   PubMed Web of Science ®Google Scholar
• KINSTLER 0, MOULINEX G, TREHEIT M et al.: Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deify. Rev. (2002) 54:477–485.
   Google Scholar
• MANJULA BN, TSAI A, UPADHYA R et al.: Site-specific PEGylation of hemoglobin at Cys-93(3): Correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG Chain. Bioconjugate Chem. (2003) 14:464–472.
   PubMed Web of Science ®Google Scholar
• ABUCHOWSKI A, VAN ES T, PALCZUK NC, DAVIS FF: Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol../. Biol. Chem. (1977) 252:3578–3581.
   PubMed Web of Science ®Google Scholar
• WORKING PK, NEWMAN SS, JOHNSON J, CORNACOFF JB: Safety of poly(ethylene glycol) derivatives. In : Poly (ethylene glycol) Chemistry and Biological Applications. Harris JM, Zalipsky S (Eds) ACS Books, Washington, DC, (1997):45–54.
   Google Scholar
• PETRAK K, GODDARD P: Transport of macromolecules across the capillary walls. Adv . Drug Deify. Rev (1989) 3:191–214.
   Google Scholar
• FRIMAN S, EGESTAD B, SJOVATT J, SVANVIK J: Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat. J. Hepatol (1993) 17:48–55.
   PubMed Web of Science ®Google Scholar
• CHOE YH, CONOVER CD, WU D et al.: Anticancer drug delivery systems: multi-loaded M-acyl poly(ethylene glycol) prodrugs of ara-C.: II. Efficacy in ascites and solid tumors J. Control. Release (2002) 79: 55–70.
   PubMed Web of Science ®Google Scholar
• SCHIAVON 0, PASUT G, MORO S, ORSOLINI P, GUIOTTO A, VERONESE FM: PEG-Ara-C conjugates for controlled release. Ear. J. Med. Chem. (2004) 39:123–133.
   PubMed Web of Science ®Google Scholar
• ORSATTI L, VERONESE FM: An unusual coupling of poly(ethylene glycol) to tyrosine residue in epidermal growth factor. j Bioac. Comp. Polymer. (1999) 14:429–436.
   Web of Science ®Google Scholar
• HARRIS JM, GUO L, FANG ZH, MORPURGO M: PEG-protein tethering for pharmaceutical applications. Seventh International Symposium on Recent Advances M Drug Delivery Salt Lake City, USA (1995).
   Google Scholar
• MONFARDINI C, SCHIAVON 0, CALICETI P, MORPURGO M, HARRIS JM, VERONESE FM: A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjugate Chem. (1995) 6:62–69.
   PubMed Web of Science ®Google Scholar
• AKIYAMA Y, OTSUKA H, NAGASAKI Y, KATO M, KATAOKA K: Selective synthesis of heterobifunctional poly(ethylene glycol) derivatives containing both mercapto and acetal terminals. Bioconjugate Chem. (2000) 11:947–950.
   PubMed Web of Science ®Google Scholar
• ZHANG S, DU J, SUN R et al.: Synthesisof heterobifunctional poly(ethylene glycol) with a primary amino group at one end and a carboxylate group at the other end. Reactive Functional Polymer (2003) 56:17–25.
   Web of Science ®Google Scholar
• DUNCAN R, CABLE HC, LLOYD JB, REJMANOVA P, KOPECEK J: Polymers containing enzimatically degradable bonds, 7. Design of oligopeptide side chains in poly N-(2-hydroxypropyl)methacrylamide copolymers to promote degradation by lysosomal enzymes. Makromol Chem. (1984) 184:1997–2008.
   Google Scholar
• REJMANOVA P, POHL J, BAUDYS M, KOSTKA V, KOPECEK J: Polymers containing enzimatically degradable bonds, 8. Degradation of oligopeptide sequences in N-(2-hydroxypropy6 methacrylamide copolymers by bovine spleen cathepsin B. Makromol Chem. (1984) 184:2009–2020.
   Google Scholar
• GREENWALD RB, YANG K, ZHAO H, CONOVER CD, LEE S, FILPULA D: Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery system employing 1,6-elimination. Bioconjugate Chem. (2003) 14:395–403.
   PubMed Web of Science ®Google Scholar
• GREENWALD RB, CHOE YH, CONOVER CD, SHUM K, WU D, ROYZEN M: Drug delivery systems based on trimethyl lock lactonisation: poly(ethylene glycol) prodrugs of amino-containing compounds. I Med. Chem. (2000) 43:475–487.
   PubMed Web of Science ®Google Scholar
• SCHIAVON 0, PASUT G, VERONESE FM: Multibranched PEG to improve the conjugate loading of Ara-C. 5th International Symposium on Polymer Therapeutics, Cardiff (UK) (2002):P62.
   Google Scholar
• HOOFTMAN G, HERMAN S, SCHACHT E: Review: poly(ethylene glycol)s with reactive endgroups. II. Practical consideration for the preparation of protein-PEG conjugates. I Bioact. Comp. Polymer (1996) 11:135–159.
   Google Scholar
• DELGADO C, FRANCIS GE, MALIK F, FISHER D, PARKES V: Polymer-derivatized proteins: analytical and preparative problems. Pharm . Sci (1997) 3:59–66.
   Google Scholar
• MONKARSH SP, MAY, AGLIONE A et al.: Positional isomers of mono-pegylated interferon a-2a: Isolation, characterization, and biological activity. Anal. Biochem. (1997) 247:434–440.
   PubMed Web of Science ®Google Scholar
• VERONESE FM, SACCA B, POLVERIDO DE LAURETO P et al: New PEGs for peptide and protein modification, suitable for identification of the PEGylation site. Bioconjugate Chem. (2001) 1:62–70.
   Google Scholar
• SATO H: Enzymatic procedure for site- specific pegylation of proteins. Adv. Drug Deity. Rev (2002) 54:487–504.
   PubMed Web of Science ®Google Scholar
• SATO H: Enzymatic procefure for site- specific pegylation of proteins. Adv. Drug Deify. Rev (2002) 54:487–504
   PubMed Web of Science ®Google Scholar
• FOLK JE: Transglutaminases. Ann. Rev Biochem. (1980) 49:517–531.
   PubMed Web of Science ®Google Scholar
• LORAND L, CONRAD SM: Transglutaminases. Ma Cell. Biochem. (1984) 58:9–35.
   PubMed Web of Science ®Google Scholar
• SATO H, YAMADA N, SHIMBA N, TAKAHRA Y: Unique substrate specificities of two adjacent glutamine residues in EAQQIVM for transglutaminase: identification and characterization of the reaction products by electrospray ionization tandem mass spectroscopy. Anal. Biochem. (2000) 281:68–76.
   PubMed Web of Science ®Google Scholar
• SATO H, YAMAMOTO K, HAYASHI E, TAKAHARA Y: Transglutaminas-mediated dual and site-specific incorporation of poly(ethylene glycol) derivatives into a chimeric interleukin-2. Bioconjugate Chem. (2000) 11(4):502–509.
   PubMed Web of Science ®Google Scholar
• COUSSONS PJ, PRICE NC, KELLY SM, JOHNSON CM, SMITH B, SAWYER L: Factors that govern the specificity of transglutaminase-catalysed modification of proteins and peptides. Biochem. .1. (1992) 282:929–930.
   PubMed Web of Science ®Google Scholar
• LORAND L, PARAMESWARAN KN, STENBERG P et al.: Specificity of guinea pig liver transglutaminase for amine substrates. Biochemistry (1979) 18:1756–1765.
   PubMed Web of Science ®Google Scholar
• UZE G, LUTFALLA G, MONGENSEN: Alpha and beta interferons and their friends and relations. J. Interferon Cytokine Res. (1995) 5:3–26.
   Google Scholar
• TYRING SK: Interferons: biochemistry and mechanisms of action. Am. J. Obstet. Cynecol (1995) 172:1350–1353.
   PubMed Web of Science ®Google Scholar
• WYLIE DC, VOLOCH M, LEE S et al.: Carboxyalkylated histidine is a pH-dependent product of pegylation with SC -PEG. Pharm. Res. (2001) 18(9):1354–1360.
   PubMed Web of Science ®Google Scholar
• WANG YS, YOUNGSTERS, BAUSCH J, ZHANG R, MCNEMAR C, WYSS DF: Identification of the major positional isomer of pegylated interferon a-2b. Biochemistry (2000) 39:10634–10640.
   PubMed Web of Science ®Google Scholar
• GLUE P, FANG JWS, SABO R et al.: PEG-interferon-a-2B: pharmacokinetics, pharmacodymanics, safety, and preliminary efficacy data. Hepatology (1999) 30 (Suppl.) :A189.
   Google Scholar
• CALICETI P, SCHIAVON 0, VERONESE FM: Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. Bioconjugate Chem. (1999) 10:638–646.
   PubMed Web of Science ®Google Scholar
• PEPINSKY RB, LE PAGE DJ, GILL A et al.: Improved phamacokinetic properties of polyethylene glycol-modified form of interferon-3-1a with preserved in vitro bioactivity.f Pharmac. Exp. Ther. (2001) 297(3):1059–1066.
   Google Scholar
• METCALF D: The molecular biology andfunctions of the granulocyte-macrophage colony-stimulating factors. Blood (1986) 67:257–267.
   PubMed Web of Science ®Google Scholar
• WELTE K, GABRILOVE J, BRONCHUD MH, PLATZER E, MORSTYN G: Filgrastrim (r-metHuG-CSF): The first 10 years. Blood (1996) 88: 1907-1929.
   Google Scholar
• KINSTLER OB, BREMS DN, LAUREN SL, PAIGE AG, HAMBURGER JB, TREUHEIT MJ: Characterization and stability of N-terminally pegylated rhG-CSE Phann. Res. (1995) 13:996–1002.
   Google Scholar
• WONG SS: Reactive groups of proteins and their modifying agents. In: Chemistry of Protein Conjugation and Cross-linking. CRC Press, Bonston. (1991):13.
   Google Scholar
• BOWEN S, BOWEN S, TARE N et al: Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol. (1999) 27:425–432.
   PubMed Web of Science ®Google Scholar
• ELIASON, JF GREWAY A, TARE N et al.:Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol. Stem Cells. (2000) 18(1):40–45.
   PubMed Web of Science ®Google Scholar
• LOK S, KAUSHANSKY K, HOLLY RD et al.: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature (1994) 369:565–568.
   PubMed Web of Science ®Google Scholar
• FARESE A, HUNT P, MACVITIE TJ: Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood (1995) 86:54.
   PubMed Web of Science ®Google Scholar
• KUTER DJ, BEELER DL, ROSEMBERG RD: The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc. Nati Acad. Sci (1994) 369:11104–11108.
   Google Scholar
• DE-BOER RH, ROSKOS LK, CHEUNG E et al.: Pharmacokinetic analysis of Pegylated megakaryocyte growth and development factor in humans. Growth Factors. (2000) 18:215–226.
   PubMed Web of Science ®Google Scholar
• GUERRA PI, ACKLIN C, KOSKY AA, DAVIS JM, TREUHEIT MJ, BREMS DN: PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor. Pharm. Res. (1998) 15:1822–1827.
   PubMed Web of Science ®Google Scholar
• CHAWLA RK, PARKS JS, RUDMAN D: Structural variants of human growth hormone: biochemical, genetic, and clinical aspects. Ann. Rev. Med. (1983) 34:519–547.
   PubMed Web of Science ®Google Scholar
• CLARK R, OLSON K, FUH G, MARIAN M et al.: Long-acting growth hormones produced by conjugation with polyethylene glycol. Biol. Chem. (1996) 271(36):21969–21977.
   Web of Science ®Google Scholar
• FROHMAN LA, JANSSON JO: Growth hormone releasing hormone. Endocc Rev (1986) 7:223–253.
   PubMed Web of Science ®Google Scholar
• LANCE VA, MURPHY WA, SUEIRAS -DIAZ J, COY DH: Superactive analogs of growth hormone-releasing factor (1-29)-amide. Biochem. Biophys. Res. Commun. (1984) 119:265–272.
   PubMed Web of Science ®Google Scholar
• ESPOSITO P, BARBERO L, CAC CIA Pet al.: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv. Drug Delivery Rev. (2003) 55:1279–1291.
   PubMed Web of Science ®Google Scholar
• PIQUET G, GATTI M, BARBERO L, TRAVERSA S, CAC CIA P, ESPOSITO P: Set-up of a large laboratory scale chromatographic separation of poly (ethylene glycol) derivatives of the growth hormone-releasing factor 1–29 analogue. " Chrom. (2002) A944:141–148.
   Google Scholar
• D'ANTONIO M, CANALI S, LOUVEAU I, ESPOSITO P: Pharmacodynamic evaluation of a PEGylated analog of human growth hormone releasing factor in rats and pigs. Growth Horm. IGF Res. (in press).
   Google Scholar
• GOFFIN V, BERNICHTEIN S, CARRIERE 0, BENNETT WE KOPCHICK JJ, KELLY PA: The human growth hormone antagonist B2036 does not interact with the prolactine receptor. Endocrinology (1999) 140:3853–3856.
   PubMed Web of Science ®Google Scholar
• PARKINSON C, SCARLETT JA TRAINER PJ: Pegvisomant in the treatment of acromegaly. Adv. Drug Delivery Rev (2003) 55:1303–1314.
   PubMed Web of Science ®Google Scholar
• SMITH KA: Interleukin-2: inception, impact, and implications. Science. (1988) 240:1169–1176.
   PubMed Web of Science ®Google Scholar
• GOODSON RJ, KATRE NV: Site-direct PEGylation of interleukin-2 at its glycosylation site. Biotechnology (1990) 8(4):343–346.
   PubMed Web of Science ®Google Scholar
• GORMAN JJ, FOLK JE: Transglutaminase amine substrates for photochemical labeling and cleavable cross-linking. Biol. Chem. (1980) 255(3):1175–1180. ao .MCDONAGH RP et al.: Amino acid sequence of the Factor XIIIa acceptor site in bovine plasma fibronectin. FEBS Lett. (1981) 127:174–178.
   Google Scholar
• SATO H, HAYASHI E, YAMADA N, YATAGAI M, TAKAHARA Y: Further studies on the site-specific protein modification by microbial transglutaminase. Bioconjugate Chem. (2001) 12(5):701–710.
   PubMed Web of Science ®Google Scholar
• KING DJ: Preparation, structure and function of monoclonal antibodies. In: Application and Engineering of Monoclonal Antibodies. Taylor and Francis, London (1998):1–26.
   Google Scholar
• KING DJ, ADAIR JR: Recombinant antibodies for the diagnosis and therapy of human disease. Curr. Opin. Drug Discov. Dev. (1999) 2:110–117.
   PubMedGoogle Scholar
• WALSH G: Biopharmaceutical benchmarks. Nat. Biotechnol. (2000) 18:831–833.
   PubMed Web of Science ®Google Scholar
• CHAPMAN AP: PEGylated antibodies andantibody fragments for improved therapy: a review. Adv. Drug Deify. Rev (2002) 54:531–545.
   PubMed Web of Science ®Google Scholar
• KOUMENIS IL, SHAHROKH Z, LEONG S, HSEI V, DEFORGE L, ZAPATA G: Modulating pharmacokinetics of an anti-interleukin-8 F(abl 2 by amine-specific PEGylation with preserved bioactivity. hat. Pharm. (2000) 198:83–95.
   Google Scholar
• ANDERSON WL, TOMASI TB: Polymer modification of antibody to eliminate immune complex and Fc binding. Immunol. Methods (1988) 109:37–42.
   PubMed Web of Science ®Google Scholar
• CHAPMAN AP, ANTONIW P, SPITALI M, WEST S, STEPHENS S, KING DJ: Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. (1999) 17: 780–783.
   PubMed Web of Science ®Google Scholar
• MAEDA H, WU J, SAWA T, MATSUMURA Y, HORI K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Control . Release (2000) 65:271–284.
   PubMed Web of Science ®Google Scholar
• TAKASHINA K, KITAMURA K, YAMAGUCHI T et al.: Comparative pharmacokinetic properties of murine monoclonal antibody Al modified with neocarzinostatin, dextran and polyethilene glycol. ". Cancer Res. (1991) 82;1145–1150.
   Google Scholar
• PEDLEY RB, BODEN JA, BODEN R, DALE R, BEGENT RH: Comparative radioimmunotherapy using intact or F(ab)2 fragments of 131I-anti-CEA antibody in a colonic xenograft model. Br. J. Cancer (1994) 70:521–525.
   PubMed Web of Science ®Google Scholar
• WEN X, WU QP, LU Y et al: Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. Bioconjugate Chem. (2001) 12:545–553.
   PubMed Web of Science ®Google Scholar
• HINDS KD, KIM SW: Effects of PEG conjugation on insulin properties. Adv. Drug Deify. Rev (2002) 54:505–530.
   PubMed Web of Science ®Google Scholar
• HOLTSBERG FW, ENSOR CM, STEINER MR, BOMALASKI JS, CLARK MA: Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.j Control. Release (2002) 80:259–271.
   PubMed Web of Science ®Google Scholar
• GREENWALD RB: PEG drugs: an overview. Control . Release (2001) 74:159–171.
   PubMed Web of Science ®Google Scholar
• •An exhaustive review on PEG-non-peptidic drug conjugates.
   Google Scholar
• GREENWALD RB, CONOVER CD, CHOE YH: Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. Crit. Rev Tiler. Drug Carr. Syst. (2000) 17:101–161.
   PubMed Web of Science ®Google Scholar
• WALL ME: Camptothecin and taxol: discovery to clinic. Med. Res. Rev (1998) 18: 299–314
   PubMed Web of Science ®Google Scholar
• POTMESIL M: Camptothecins: from bench research to hospital wards. Cancer Res. (1994) 54: 1431–1439.
   PubMed Web of Science ®Google Scholar
• HARADA M, SAKAKIBARA H, YANO T, SUZUKI T, OKUNO S: Determinants for the drug release from T-0 1 2 8, camptothecin analogue-carboxymethyl dextran conjugate. " Control. Release (2000) 69:399–412.
   PubMed Web of Science ®Google Scholar
• SINGER JW, DE VRIES P, BHATT R et al.: Conjugation of Camptothecins to Poly-(1-Glutamic Acid). Ann. NY Acad. Sci. (2000) 922:136–150.
   PubMed Web of Science ®Google Scholar
• CAIOLFA VR, ZAMAI M, FIORINO A et al.: Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. Control. Release (2000) 65:105–119.
   PubMed Web of Science ®Google Scholar
• CARL P, CHAKRAVARTY P, KATZENELLENBOGEN J: A novel connector linkage applicable in prodrug design. Med. Chem. (1981) 24:479–480.
   Web of Science ®Google Scholar
• GREENWALD RB, PENDRI A, CONOVER CD et al.: Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. Bioorg. Med. Chem. (1998) 6:551–562.
   PubMed Web of Science ®Google Scholar
• CONOVER CD, GREENWALD RB, PENDRI A, SHUM KL: Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anticancer Drug Des. (1999) 14:499–506.
   PubMedGoogle Scholar
• GUIOTTO A, CANEVARI M, ORSOLINI P et al.: Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethykamptothecin. J. Med. Chem. (2004) 47:1280–1289.
   PubMed Web of Science ®Google Scholar
• GREENWALD RB, PENDRI A, CONOVER CD et al: Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds. I Med. Chem. (1999) 42:3657–3667.
   PubMed Web of Science ®Google Scholar
• RIEBESEEL K, BIEDERMANN E, LOSER R et al.: Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships M vitro and in vivo. Bioconjug. Chem. (2002) 13:773–785.
   PubMed Web of Science ®Google Scholar
• FURIN A, GUIOTTO A, BACCICHETTI F et al: Synthesis, characterization and preliminary cytotoxicity assays of poly(ethylene glycol) (PEG)-malonato-Pt-DACH conjugates. Eur. Med. Chem. (2003) 38:739–749.
   PubMed Web of Science ®Google Scholar
• ARONOV 0, HOROWITZ AT, GABIZON A, GIBSON D: Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and M vitro studies. Bioconjugate Chem. (2003) 14:563–574.
   PubMed Web of Science ®Google Scholar
• CHOE YH, CONOVER CD, WU D, ROYZEN M, GREENWALD RB: Anticancer drug delivery systems: Ni-acyl poly(ethyleneglycol) prodrugs of ara-C: I. Efficacy in solid tumors. Control. Release (2002) 79:41–53.
   PubMed Web of Science ®Google Scholar
• GREENWALD RB, GILBERT CW, PENDRI A, CONOVER CD, XIA J, MARTINEZ A: Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs -design and in vivo effectiveness Med. Chem. (1996) 39:424–431.
   Web of Science ®Google Scholar
• FENG X, YUAN Y-J, WU J-C: Synthesis and evaluation of water-soluble paclitaxel prodrugs Bioorg. Med. Chem. Lett. (2002) 12:3301–3303.
   PubMed Web of Science ®Google Scholar
• ROUQUAYROL M, GAUCHER B, ROCHE D, GREINER J, VIERLING P: Transepithelial transport of prodrugs of the HIV protease inhibitors Saquinavir, Indinavir, and Nelfinavir across Caco-2 cell monolayers. Pharm. Res. (2002) 19:1704–1712.
   PubMed Web of Science ®Google Scholar
• ZACCHIGNA M, DI LUCA G, MAURICH V, BOCCD E: Syntheses, chemical and enzymatic stability of new poly(ethylene glycol)-acyclovir prodrugs. Farmaco (2002) 57:207–214.
   PubMedGoogle Scholar
• CONOVER CD, ZHAO H, LONGLEY CB, SHUM KL, GREENWALD RB: Utility of poly(ethylene glycol) conjugation to create prodrugs of Amphotericin B. Bioconjugate Chem. (2003) 14:661–666.
   PubMed Web of Science ®Google Scholar
• ABUCHOWSKI A, MCCOY R, PALCZUK NC, VAN ES T, DAVIS FF: Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. I Biol. Chem. (1977) 252:3582–3586.
   Web of Science ®Google Scholar
• ALLEN TM: Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer (2002) 2:750–763.
   PubMed Web of Science ®Google Scholar
• DUNCAN R: The dawning era of polymer therapeutics. Nat. Rev Drug Discov. (2003) 2:347–360.
   PubMed Web of Science ®Google Scholar
• •An important overview of the polymers used for therapeutic purposes.
   Google Scholar